Log in

Relevant bibliographies by topics / Lung transplants; Rejection / Journal articles

To see the other types of publications on this topic, follow the link: Lung transplants; Rejection.

Journal articles on the topic 'Lung transplants; Rejection'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lung transplants; Rejection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Schersten, H., H. D. Tazelaar, A. R. Cale, V. M. Miller, and C. G. McGregor. "Systemic vascular effects during acute rejection of lung allografts." American Journal of Physiology-Heart and Circulatory Physiology 270, no. 6 (1996): H2191—H2196. http://dx.doi.org/10.1152/ajpheart.1996.270.6.h2191.

Full text

Abstract:

Circulating leukocytes activated during rejection of organ allografts could potentially have generalized effects on systemic blood vessels of the transplant recipient. Experiments were designed, therefore, to determine the function of the endothelium and smooth muscle of arteries from nontransplanted organs in dogs who received single lung transplants. Dogs underwent single lung allotransplantation and were immunosuppressed for 5 days. Immunosuppression was then withheld for 3 days, allowing rejection to occur. Dogs were studied at this time (rejecting) or following treatment for rejection for

APA, Harvard, Vancouver, ISO, and other styles

2

Weber, Daniel J., and David S. Wilkes. "The role of autoimmunity in obliterative bronchiolitis after lung transplantation." American Journal of Physiology-Lung Cellular and Molecular Physiology 304, no. 5 (2013): L307—L311. http://dx.doi.org/10.1152/ajplung.00378.2012.

Full text

Abstract:

First performed in the 1960s with long-term successes achieved in the 1980s, lung transplantation remains the only definitive treatment option for end-stage lung disease. Chronic lung rejection, pathologically classified as obliterative bronchiolitis (OB) with its clinical correlate referred to as bronchiolitis obliterans syndrome, is the limiting factor than keeps 5-yr survival rates for lung transplant significantly worse than for other solid organ transplants. Initially, OB was largely attributed to immune responses to donor antigens, alloimmunity. However, more recent work has demonstrated

APA, Harvard, Vancouver, ISO, and other styles

3

Spector, NM, MA Connolly, and Garrity ERJr. "Lung transplant rejection: obliterative bronchiolitis." American Journal of Critical Care 5, no. 5 (1996): 366–72. http://dx.doi.org/10.4037/ajcc1996.5.5.366.

Full text

Abstract:

BACKGROUND: More centers are performing lung transplants for a variety of pulmonary conditions. Chronic rejection, manifested as obliterative bronchiolitis, is the most common cause of late death (greater than 6 months after transplant) in this population. OBJECTIVES: To review published literature on obliterative bronchiolitis to determine the current terminology and definition, pathophysiology, incidence, diagnosis, treatment, and outcome of this condition. DATA SELECTION: A MEDLINE search was done using the medical subject headings of bronchiolitis obliterans and lung transplantation. Studi

APA, Harvard, Vancouver, ISO, and other styles

4

Fisher, Andrew, Anders Andreasson, Alexandros Chrysos, et al. "An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK." Health Technology Assessment 20, no. 85 (2016): 1–276. http://dx.doi.org/10.3310/hta20850.

Full text

Abstract:

BackgroundMany patients awaiting lung transplantation die before a donor organ becomes available. Ex vivo lung perfusion (EVLP) allows initially unusable donor lungs to be assessed and reconditioned for clinical use.ObjectiveThe objective of the Donor Ex Vivo Lung Perfusion in UK lung transplantation study was to evaluate the clinical effectiveness and cost-effectiveness of EVLP in increasing UK lung transplant activity.DesignA multicentre, unblinded, non-randomised, non-inferiority observational study to compare transplant outcomes between EVLP-assessed and standard donor lungs.SettingMultice

APA, Harvard, Vancouver, ISO, and other styles

5

Song, Mi-Kyung, Annette De Vito Dabbs, Sean M. Studer, and Sarah E. Zangle. "Course of Illness after the Onset of Chronic Rejection in Lung Transplant Recipients." American Journal of Critical Care 17, no. 3 (2008): 246–53. http://dx.doi.org/10.4037/ajcc2008.17.3.246.

Full text

Abstract:

Background Despite the overall negative impact of chronic rejection on quality of life and survival after lung transplant, the specific clinical indicators of deterioration have not been identified. Objectives To describe the course of illness after the onset of chronic rejection, including demographic and transplant variables, morbidity, mortality, health resource utilization, and end-of-life care, and to identify clinical indicators of deterioration in health and limited survival after the onset of chronic rejection. Methods The medical records of 311 recipients of lung transplants between 1

APA, Harvard, Vancouver, ISO, and other styles

6

DeVito Dabbs, Annette, Leslie A. Hoffman, Aldo T. Iacono, et al. "Pattern and Predictors of Early Rejection After Lung Transplantation." American Journal of Critical Care 12, no. 6 (2003): 497–507. http://dx.doi.org/10.4037/ajcc2003.12.6.497.

Full text

Abstract:

• Background Most lung transplant recipients experience improvement in their underlying pulmonary condition but are faced with the threat of allograft rejection, the primary determinant of long-term survival. Several studies examined predictors of rejection, but few focused on the early period after transplantation. • Objectives To describe the pattern and predictors of early rejection during the first year after transplantation to guide the development of interventions to facilitate earlier detection and treatment of rejection. • Methods Data for donor, recipient, and posttransplant variables

APA, Harvard, Vancouver, ISO, and other styles

7

Nosotti, Mario, Frank D’Ovidio, Miguel Leiva-Juarez, et al. "Rare indications for a lung transplant. A European Society of Thoracic Surgeons survey." Interactive CardioVascular and Thoracic Surgery 31, no. 5 (2020): 638–43. http://dx.doi.org/10.1093/icvts/ivaa165.

Full text

Abstract:

Abstract OBJECTIVES The European Society of Thoracic Surgeons Lung Transplantation Working Group promoted a survey to evaluate overall survival in a large cohort of patients receiving lung transplants for rare pulmonary diseases. METHODS We conducted a retrospective multicentre study. The primary end point was overall survival; secondary end points were survival of patients with the most common diagnoses in the context of rare pulmonary diseases and chronic lung allograft dysfunction (CLAD)-free survival. Finally, we analysed risk factors for overall survival and CLAD-free survival. RESULTS Cl

APA, Harvard, Vancouver, ISO, and other styles

8

Kim, Edward, Hin Hin Ko, and Eric M. Yoshida. "A Concise Review of Hepatitis C in Heart and Lung Transplantation." Canadian Journal of Gastroenterology 25, no. 8 (2011): 445–48. http://dx.doi.org/10.1155/2011/947838.

Full text

Abstract:

Hepatitis C (HCV) infection is prevalent in recipients of, and candidates for, solid organ transplants. The outcomes of HCV infection in cardiac and lung transplant recipients have yet to be clearly established, and future prospective studies are needed. In the absence of safe and effective antiviral treatment for HCV infection in heart and lung transplant recipients, the management of these patients remains a challenge and must be considered on an individual basis. Interferon therapy for HCV before transplantation appears to improve outcomes; however, post-transplant interferon therapy in the

APA, Harvard, Vancouver, ISO, and other styles

9

Husain, Aliya N., and Edward R. Garrity. "Lung Transplantation: The State of the Airways." Archives of Pathology & Laboratory Medicine 140, no. 3 (2016): 241–44. http://dx.doi.org/10.5858/arpa.2015-0295-sa.

Full text

Abstract:

Context Lung transplantation has become a viable option for definitive treatment of several end-stage lung diseases for which there are no other options available. However, long-term survival continues to be limited by chronic lung allograft dysfunction, which primarily affects the airways. Objective —To highlight the complications occurring mainly in the airways of the lung transplant recipient from the early to late posttransplant periods. Data Sources Review literature focusing on the airways in patients with lung transplants and clinical experience of the authors. Conclusions Postsurgical

APA, Harvard, Vancouver, ISO, and other styles

10

De Vlaminck, Iwijn, Lance Martin, Michael Kertesz, et al. "Noninvasive monitoring of infection and rejection after lung transplantation." Proceedings of the National Academy of Sciences 112, no. 43 (2015): 13336–41. http://dx.doi.org/10.1073/pnas.1517494112.

Full text

Abstract:

The survival rate following lung transplantation is among the lowest of all solid-organ transplants, and current diagnostic tests often fail to distinguish between infection and rejection, the two primary posttransplant clinical complications. We describe a diagnostic assay that simultaneously monitors for rejection and infection in lung transplant recipients by sequencing of cell-free DNA (cfDNA) in plasma. We determined that the levels of donor-derived cfDNA directly correlate with the results of invasive tests of rejection (area under the curve 0.9). We also analyzed the nonhuman cfDNA as a

APA, Harvard, Vancouver, ISO, and other styles

11

Halverson, Laura P., and Ramsey R. Hachem. "Antibody-Mediated Rejection and Lung Transplantation." Seminars in Respiratory and Critical Care Medicine 42, no. 03 (2021): 428–35. http://dx.doi.org/10.1055/s-0041-1728796.

Full text

Abstract:

AbstractAntibody-mediated rejection (AMR) is now a widely recognized form of lung allograft rejection, with mounting evidence for AMR as an important risk factor for the development of chronic lung allograft dysfunction and markedly decreased long-term survival. Despite the recent development of the consensus diagnostic criteria, it remains a challenging diagnosis of exclusion. Furthermore, even after diagnosis, treatment directed at pulmonary AMR has been nearly exclusively derived from practices with other solid-organ transplants and other areas of medicine, such that there is a significant

APA, Harvard, Vancouver, ISO, and other styles

12

Troxell, Megan L., and Christian Lanciault. "Practical Applications in Immunohistochemistry: Evaluation of Rejection and Infection in Organ Transplantation." Archives of Pathology & Laboratory Medicine 140, no. 9 (2016): 910–25. http://dx.doi.org/10.5858/arpa.2015-0275-cp.

Full text

Abstract:

Context.—Immunohistochemical analysis of tissue biopsy specimens is a crucial tool in diagnosis of both rejection and infection in patients with solid organ transplants. In the past 15 years, the concept of antibody-mediated rejection has been refined, and diagnostic criteria have been codified in renal, heart, pancreas, and lung allografts (with studies ongoing in liver, small intestine, and composite grafts), all of which include immunoanalysis for the complement split product C4d. Objectives.—To review the general concepts of C4d biology and immunoanalysis, followed by organ-allograft–speci

APA, Harvard, Vancouver, ISO, and other styles

13

Singh, Ankur. "T cells, the last samurai against humoral rejection in lung transplants." Science Translational Medicine 11, no. 475 (2019): eaaw5313. http://dx.doi.org/10.1126/scitranslmed.aaw5313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hassan, Noha Abdelwahab, Ala Abudayyeh, Mohsin Shah, Daniel Hartman Johnson, Maria E. Suarez-Almazor, and Adi Diab. "The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature." Journal of Clinical Oncology 36, no. 5_suppl (2018): 41. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.41.

Full text

Abstract:

41 Background: Solid organ transplant recipients have been excluded from Checkpoint inhibitors (CPI) clinical trials because of the concern of allo-immunity and possible organ rejection. Methods: We searched 5 databases through September 2017. Studies describing the use of CPI to treat cancer in solid organ transplant Patients (pts), and provided detailed description of each case were included. Results: Sixteen publications met inclusion criteria, reporting on 19 cases. Median age of pts was 59 (14-77) yrs and 74% were male. Cancer types included melanoma (n=11), cutaneous squamous cell carcin

APA, Harvard, Vancouver, ISO, and other styles

15

Zampieri, Davide, Nadia Azzollini, Stefania Vuljan, et al. "Vein Suturing Results in Worse Lung Graft Outcomes Compared to the Cuff Method." European Surgical Research 60, no. 3-4 (2019): 106–16. http://dx.doi.org/10.1159/000501805.

Full text

Abstract:

Background: The rat orthotopic lung transplant model is not widely used yet because of the complexity of the procedure, in particular, venous anastomosis. Here, we performed a rat orthotopic lung transplantation using either the suture (ST) or cuff (CT) method for vein anastomosis. Objectives: To compare the vein ST and CT techniques in terms of operative time, success, recipient survival, and early histological outcomes was the objective of this study. Methods: A total of 24 left lung transplants in rats were performed. Twelve syngeneic (Lewis to Lewis) and 12 allogeneic (Brown-Norway to Lewi

APA, Harvard, Vancouver, ISO, and other styles

16

Shilling, Rebecca A. "Harnessing Natural Killer Cells to Protect Lung Transplants from Acute Rejection." American Journal of Respiratory and Critical Care Medicine 187, no. 12 (2013): 1284–86. http://dx.doi.org/10.1164/rccm.201304-0634ed.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Morton, Lindsay M., Christina A. Clarke, Ellen T. Chang, et al. "Risk of Acute Myeloid Leukemia Among Solid Organ Transplant Recipients." Blood 118, no. 21 (2011): 2559. http://dx.doi.org/10.1182/blood.v118.21.2559.2559.

Full text

Abstract:

Abstract Abstract 2559 Background. Patients receiving solid organ transplants experience increased risk of subsequent hematologic malignancies, particularly post-transplant lymphoproliferative disorder and non-Hodgkin lymphoma, likely in relation to infection with oncogenic viruses and pharmacologic immunosuppression to prevent graft rejection. However, less is known about the risks for myeloid neoplasms such as acute myeloid leukemia (AML). Methods. We linked data from the US Scientific Registry of Transplant Recipients, a national database of solid organ transplantation, with 13 state and re

APA, Harvard, Vancouver, ISO, and other styles

18

Horn, Monica V., Felicia A. Schenkel, Marlyn S. Woo, and Vaughn A. Starnes. "Pediatric Recipients of Living Donor Lobar Lung Transplants: Postoperative Care." Progress in Transplantation 12, no. 2 (2002): 81–85. http://dx.doi.org/10.1177/152692480201200202.

Full text

Abstract:

Bilateral living donor lobar lung transplantation is a treatment option for selected children and adults with end-stage lung disease. Careful donor evaluation, skilled intraoperative management and surgical technique, and diligent immediate postoperative care and follow-up all contribute to better outcomes. Although medical management of whole lung transplant recipients in the immediate postoperative period is similar to that of lobar lung transplant recipients, there are specific differences. Anatomical distinctions, such as the entire cardiac output flowing to 2 lobes instead of 5, and thora

APA, Harvard, Vancouver, ISO, and other styles

19

Thompson, Melissa L., Jeremy D. Flynn, and Timothy M. Clifford. "Pharmacotherapy of Lung Transplantation." Journal of Pharmacy Practice 26, no. 1 (2012): 5–13. http://dx.doi.org/10.1177/0897190012466048.

Full text

Abstract:

Lung transplantation has become a viable treatment therapy for end-stage lung disease patients. The most common etiologies of end-stage lung disease, which can require a transplant are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and pulmonary fibrosis (PF). Listing criteria are institution and program specific. Approximately 1500 lung transplants were performed in 2008; and at 5 years post transplant, one-half are expected to survive. The surgery itself is associated with various complications, including surgical, in

APA, Harvard, Vancouver, ISO, and other styles

20

(Michael) Ji, Xincheng, Raksha Jain, and David E. Greenberg. "2663. Impact of Pre-Transplant Microbiology on Acute Outcomes in Cystic Fibrosis Patients Receiving Bilateral Lung Transplants." Open Forum Infectious Diseases 6, Supplement_2 (2019): S932. http://dx.doi.org/10.1093/ofid/ofz360.2341.

Full text

Abstract:

Abstract Background Lung transplantation is a life-prolonging intervention for cystic fibrosis (CF) patients; however, their tendency to be colonized with multiple respiratory pathogens poses a unique risk for post-transplant complications. While infections with certain CF-related pathogens have been identified as contraindications for transplant, much remains uncertain about the influence of pre-transplant microbiological factors on post-transplant outcomes. Methods A retrospective cohort study was performed for all CF patients receiving bilateral lung transplants at a single center during th

APA, Harvard, Vancouver, ISO, and other styles

21

Halloran, Kieran, Michael D. Parkes, Irina L. Timofte, et al. "Molecular phenotyping of rejection‐related changes in mucosal biopsies from lung transplants." American Journal of Transplantation 20, no. 4 (2019): 954–66. http://dx.doi.org/10.1111/ajt.15685.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Winter, Jobst B., Colin Clelland, Annette S. H. Gouw, and Jochum Prop. "DISTINCT PHENOTYPES OF INFILTRATING CELLS DURING ACUTE AND CHRONIC LUNG REJECTION IN HUMAN HEART-LUNG TRANSPLANTS." Transplantation 59, no. 1 (1995): 63–69. http://dx.doi.org/10.1097/00007890-199501150-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Clelland, Colin A., Timothy W. Higenbottam, Susan Stewart, John P. Scott, and John Wallwork. "The histological changes in transbronchial biopsy after treatment of acute lung rejection in heart-lung transplants." Journal of Pathology 161, no. 2 (1990): 105–12. http://dx.doi.org/10.1002/path.1711610204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gregson, Aric L., Aki Hoji, Patil Injean, et al. "Altered Exosomal RNA Profiles in Bronchoalveolar Lavage from Lung Transplants with Acute Rejection." American Journal of Respiratory and Critical Care Medicine 192, no. 12 (2015): 1490–503. http://dx.doi.org/10.1164/rccm.201503-0558oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Lee, Soyoung, Akihiro Aoyama, Makoto Tonsho, et al. "Anti-IL-6R antibodies prevent acute rejection of allogeneic lung transplants in monkeys." Journal of the American College of Surgeons 215, no. 3 (2012): S137—S138. http://dx.doi.org/10.1016/j.jamcollsurg.2012.06.354.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Lee, S., A. Aoyama, M. Tonsho, et al. "Anti-IL-6R Antibodies Prevent Acute Rejection of Allogeneic Lung Transplants in Monkeys." Transplantation Journal 94, no. 10S (2012): 189. http://dx.doi.org/10.1097/00007890-201211271-00353.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Gelman, Andrew E., Mikio Okazaki, Jiaming Lai, et al. "CD4+T Lymphocytes Are Not Necessary for the Acute Rejection of Vascularized Mouse Lung Transplants." Journal of Immunology 180, no. 7 (2008): 4754–62. http://dx.doi.org/10.4049/jimmunol.180.7.4754.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Yamada, Y., J. Jang, I. De Meester, I. Inci, W. Weder, and W. Jungraithmayr. "Acute Allograft Rejection Is Attenuated By CD26-Inhibition Through IL-17 Suppression in Mouse Lung Transplants." Journal of Heart and Lung Transplantation 34, no. 4 (2015): S52. http://dx.doi.org/10.1016/j.healun.2015.01.130.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Penketh, A. R., T. W. Higenbottam, J. Hutter, C. Coutts, S. Stewart, and J. Wallwork. "Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants." Thorax 43, no. 10 (1988): 762–69. http://dx.doi.org/10.1136/thx.43.10.762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Jagadeesh, Deepa, Sharjeel Hooda, Kathleen B. Fenner, et al. "Post Transplant Lymphoproliferative Disorders (PTLD) after Solid Organ Transplant: Cleveland Clinic Experience." Blood 124, no. 21 (2014): 3008. http://dx.doi.org/10.1182/blood.v124.21.3008.3008.

Full text

Abstract:

Abstract Background: Post transplant lymphoproliferative disorders (PTLD) are rare pathologically and clinically heterogeneous diseases arising in the setting of immunosuppression following hematopoietic stem cell and solid organ transplants (SOT). Our understanding of PTLD is restricted by its low incidence and heterogeneous treatment approaches, resulting in paucity of data. We sought to further describe characteristics and outcomes in PTLD patients who underwent treatment at our institution. Methods and Patients: We performed a retrospective study to describe our institutional experience in

APA, Harvard, Vancouver, ISO, and other styles

31

Okazaki, M., A. S. Krupnick, C. G. Kornfeld, et al. "350: CD4 T lymphocytes are not necessary for the acute rejection of vascularized orthotopic allogeneic mouse lung transplants." Journal of Heart and Lung Transplantation 26, no. 2 (2007): S185. http://dx.doi.org/10.1016/j.healun.2006.11.370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

He, Yuelin, Xuedong Wu, Yongsheng Ruan та ін. "Hematopoietic Stem Cell Transplantation for Patients with β-Thalassemia Major Underwent Pre-Transplant Splenectomy". Blood 124, № 21 (2014): 5932. http://dx.doi.org/10.1182/blood.v124.21.5932.5932.

Full text

Abstract:

Abstract Current study analyses the effect of splenectomy on outcomes of hematopoietic stem cell transplantation (HSCT) for patients with β-thalassemia major (TM). Twenty-two class II and III (according to Nanfang’s criteria, see Blood, 2012;120 (19): 3875-3881) patients with TM had a pre-transplant splenectomy. The outcomes of the 22 transplants were compared with 193 transplants in class II and III patients between Aug. 2008 and Dec. 2013. Patients in the splenectomy group were older (8.9±5.0 vs. 6.0±3.5 year old; p=0.001) and class III patients were more (8/22 vs. 10/193, p=0.001) than non-

APA, Harvard, Vancouver, ISO, and other styles

33

Ishibashi, Naoya, Tatsuaki Watanabe, Masahiko Kanehira, et al. "Bone marrow mesenchymal stromal cells protect allograft lung transplants from acute rejection via the PD-L1/IL-17A axis." Surgery Today 48, no. 7 (2018): 726–34. http://dx.doi.org/10.1007/s00595-018-1643-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Wudhikarn, Kitsada, Carol J. Holman, Anne H. Blaes, Jordan M. Dunitz, Marshall I. Hertz, and Bruce A. Peterson. "Post Transplant Lymphoproliferative Disorders (PTLD) After Lung Transplantation: Comparison of Patients with Early Versus Late Disease." Blood 114, no. 22 (2009): 3947. http://dx.doi.org/10.1182/blood.v114.22.3947.3947.

Full text

Abstract:

Abstract Abstract 3947 Poster Board III-883 The incidence and natural history of post-transplant lymphoproliferative disorders (PTLD) vary considerably after different types of organ transplantation. Lung and heart-lung transplants pose a higher risk of PTLD than kidney, pancreas or liver transplantation, most likely due to higher intensity post transplant immunosuppression. While the number of lung transplants is growing, there are only a few studies that detail PTLD in this setting. We studied 33 PTLD patients identified among 639 lung transplant recipients (5.1%) seen at the University of M

APA, Harvard, Vancouver, ISO, and other styles

35

Szabolcs, Paul, Rebecca Buckley, Robert Duane Davis, et al. "Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution." Blood 118, no. 21 (2011): 1006. http://dx.doi.org/10.1182/blood.v118.21.1006.1006.

Full text

Abstract:

Abstract Abstract 1006 Here we report on the clinical course and immunologic recovery of a 17 year old patient with combined immunodeficiency disease (CID) requiring bilateral orthotopic lung tranplantaion (BOLT) followed by bone marrow transplant from the same unrelated cadaveric donor. Recurrent stenotrophomonas pneumonias since age 5 along with atypical mycobacterium and E. coli infections resulted in pulmonary failure by age 15 years. Chronic hypoxia and recurrent infectious gastroenteritis led to severe growth failure necessitating total parental nutrition. She presented in 2009 with the

APA, Harvard, Vancouver, ISO, and other styles

36

Korobka, V. L., M. Yu Kostrykin, E. S. Pak, R. O. Dabliz, O. V. Kotov, and A. M. Shapovalov. "A five-year liver transplant experience in Rostov Oblast." Russian Journal of Transplantology and Artificial Organs 22, no. 2 (2020): 35–43. http://dx.doi.org/10.15825/1995-1191-2020-2-35-43.

Full text

Abstract:

Objective: to reflect on a 5-year experience in liver transplant surgery at the Rostov Regional Clinical Hospital. Materials and methods. Liver transplant was performed in Rostov Oblast in July 2015 for the first time. There were 52 liver transplant surgeries performed in the region by the end of February 2020. Cirrhosis due to viral hepatitis is the leading indication for liver transplantation in 33.3% of patients. The average age of recipients was 43.5 ± 15.8 years. Male recipients accounted for 59.6% of cases. Nine recipients got liver transplants from blood relatives, while 43 recipients r

APA, Harvard, Vancouver, ISO, and other styles

37

Yoshida, S., A. Haque, T. Mizobuchi, et al. "Anti-Type V Collagen Lymphocytes that Express IL-17 and IL-23 Induce Rejection Pathology in Fresh and Well-Healed Lung Transplants." American Journal of Transplantation 6, no. 4 (2006): 724–35. http://dx.doi.org/10.1111/j.1600-6143.2006.01236.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hinze, Alicia M., Cheng T. Lin, Amira F. Hussien, et al. "Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma." Rheumatology 59, no. 4 (2019): 790–98. http://dx.doi.org/10.1093/rheumatology/kez341.

Full text

Abstract:

Abstract Objective To investigate the natural history of fibrotic lung disease in recipients of a single lung transplant for scleroderma-associated interstitial lung disease (ILD). Methods Global ILD (including ground glass, nodular opacities and fibrosis) was categorized into severity quintiles on first and last post-transplant CT scans, and percent fibrosis by manual contouring was also determined, in nine single lung transplant recipients. Quantitative mean lung densities and volumes for the native and allograft lungs were also acquired. Results In the native lung, global ILD severity quint

APA, Harvard, Vancouver, ISO, and other styles

39

Shenoy, K. V., C. Solomides, F. Cordova, T. J. Rogers, D. Ciccolella, and G. J. Criner. "Low CD4/CD8 Ratio in Bronchus-Associated Lymphoid Tissue Is Associated with Lung Allograft Rejection." Journal of Transplantation 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/928081.

Full text

Abstract:

Background. Bronchus-associated lymphoid tissue (BALT) has been associated with lung allograft rejection in rat transplant models. In human transplant recipients, BALT has not been linked to clinically significant rejection. We hypothesize that the immunohistochemical composition of BALT varies with the presence of acute lung allograft rejection.Methods. We retrospectively examined 40 human lung allograft recipients transplanted from 3/1/1999 to 6/1/2008. Patients were grouped by frequency and severity of acute rejection based on International Society of Heart Lung Transplant (ISHLT) criteria.

APA, Harvard, Vancouver, ISO, and other styles

40

Wiklund, L., V. M. Miller, H. D. Tazelaar, and C. G. McGregor. "Effects of mononuclear cells on pulmonary arteries from rejecting transplanted lungs." American Journal of Physiology-Lung Cellular and Molecular Physiology 272, no. 3 (1997): L379—L384. http://dx.doi.org/10.1152/ajplung.1997.272.3.l379.

Full text

Abstract:

Experiments were designed to determine responses of pulmonary arteries from an acutely rejecting, transplanted lung to rejection-activated mononuclear cells. Pulmonary arteries and macrophage-depleted mononuclear cells were obtained from unoperated dogs (control) and dogs with rejecting single lung allotransplants (transplanted, rejecting). In some arteries, the endothelium was removed deliberately. Pulmonary arteries were suspended for measurement of isometric force in organ chambers. Contractions to potassium chloride (60 M) were greater in rings of pulmonary arteries from rejecting compared

APA, Harvard, Vancouver, ISO, and other styles

41

Fioredda, Francesca, Elisabeth T. Korthof, Simona Iacobelli, et al. "Outcome of BONE Marrow Transplantation in Congenital Diskeratosis: Preliminary DATA from the European Group for BONE Marrow Transplantation (EBMT)." Blood 126, no. 23 (2015): 3623. http://dx.doi.org/10.1182/blood.v126.23.3623.3623.

Full text

Abstract:

Abstract Hematopoietic Stem cell Transplantation (HSCT) is the definitive treatment for bone marrow failure in diskeratosis congenita (DC). Organ dysfunction (mainly lung and gastrointestinal tract) are often part of the disease and may be a limiting factor for or may affect the final outcome of HSCT. Scarce data or relatively small cohort studies are available in current literature on outcome of HSCT in this disease. We analyzed the outcome of 87 patients diagnosed with DC reported in the data base of the European Society for Blood an Bone Marrow Transplantation (EBMT) who underwent HSCT from

APA, Harvard, Vancouver, ISO, and other styles

42

Oosterhoff, Ytske, Jacobien A. Noordhoek, Arjen H. Petersen, Henk F. Kauffman, Dirkje S. Postma, and Jochum Prop. "There Is No Activation of O2−Production by Alveolar Macrophages and Neutrophil Polymorphonuclear Leukocytes in Rat Lung Transplants during the Reimplantation Response and Acute Rejection." American Review of Respiratory Disease 145, no. 5 (1992): 1155–59. http://dx.doi.org/10.1164/ajrccm/145.5.1155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Euler, André, Christian Blüthgen, Moritz C. Wurnig, Wolfgang Jungraithmayr, and Andreas Boss. "Can texture analysis in ultrashort echo‐time MRI distinguish primary graft dysfunction from acute rejection in lung transplants? A multidimensional assessment in a mouse model." Journal of Magnetic Resonance Imaging 51, no. 1 (2019): 108–16. http://dx.doi.org/10.1002/jmri.26817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Sumpter, Tina L., and David S. Wilkes. "Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection." American Journal of Physiology-Lung Cellular and Molecular Physiology 286, no. 6 (2004): L1129—L1139. http://dx.doi.org/10.1152/ajplung.00330.2003.

Full text

Abstract:

Lung transplantation is the only definitive treatment modality for many forms of end-stage lung disease. However, the lung is rejected more often than any other type of solid organ allograft due to chronic rejection known as bronchiolitis obliterans (BO). Indeed, BO is the primary reason why the 5- and 7-yr survival rates are worse for the lung than for any other transplanted organ. Alloimmunity to donor antigens is established as the primary mechanism that mediates rejection responses. However, newer immunosuppressive regimens designed to abrogate alloimmune activation have not improved survi

APA, Harvard, Vancouver, ISO, and other styles

45

Hering, B. J., C. C. Browatzki, A. Schultz, R. G. Bretzel, and K. F. Federlin. "Clinical Islet Transplantation — Registry Report, Accomplishments in the past and Future Research Needs." Cell Transplantation 2, no. 4 (1993): 269–82. http://dx.doi.org/10.1177/096368979300200403.

Full text

Abstract:

This review provides the results of a recent analysis of the Islet Transplant Registry on clinical adult islet transplants performed worldwide through June 30, 1992. Between December 12, 1893 and June 30, 1992, 167 adult islet transplants were performed at 25 institutions worldwide, including 104 at 9 institutions in North America, 62 at 15 institutions in Europe, and 1 elsewhere. The total number of diabetic patients reported to be insulin independent after adult islet allotransplantation through June 30,1992, was 19. In an analysis by era, the percentage of patients that showed positive basa

APA, Harvard, Vancouver, ISO, and other styles

46

Gomez-Arteaga, Alexandra, Danielle Guarneri, Usama Gergis, et al. "Cord Blood Transplants Supported By Unrelated Donor CD34 Progenitor Cells." Blood 132, Supplement 1 (2018): 4646. http://dx.doi.org/10.1182/blood-2018-99-115502.

Full text

Abstract:

Abstract Introduction: Umbilical cord blood (UCB) transplant supported by third party CD34-selected cells results in rapid count recovery, UCB mediated GVL effects and low rates of chronic GvHD. For patients lacking haplo-identical relatives, other sources of CD34 progenitors are needed. Methods: We identified partially matched unrelated donors for patients lacking suitable haplo-identical donors -including second-degree relatives - and who otherwise were candidates for haplo-cord transplant. Most were treated on prospective studies (clinicaltrials.gov 00943800 and 01810588). For 5 patients, U

APA, Harvard, Vancouver, ISO, and other styles

47

Cipriani, Lynne, and Sarah A. Martin. "Current Controversies in Pediatric Transplantation." AACN Advanced Critical Care 5, no. 3 (1994): 263–77. http://dx.doi.org/10.4037/15597768-1994-3006.

Full text

Abstract:

Transplantation in children has become a therapeutic option for several end stage organ diseases. The kidney, liver, and heart are the most common organs transplanted; however, an increasing number of children are undergoing successful intestine, lung, and multiple organ transplant combinations. Through case study reports, emerging transplant options for the child experiencing end stage liver, intestine, heart, and lung failure are described. Critical care nurses play a crucial role in the postoperative recovery of these patients. An understanding of the transplant process and consequences of

APA, Harvard, Vancouver, ISO, and other styles

48

Miller, Weston, Caleb E. Wheeler, Angela Panoskaltsis-Mortari, et al. "Prevention of Acute GvHD During MHC Haploidentical BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model." Blood 114, no. 22 (2009): 2455. http://dx.doi.org/10.1182/blood.v114.22.2455.2455.

Full text

Abstract:

Abstract Abstract 2455 Poster Board II-432 Introduction: While hematopoietic stem cell transplantation (HSCT) offers a cure for many hematologic diseases, it remains plagued by often fatal graft-versus-host disease (GvHD). Despite the inadequacy of current GvHD prevention strategies, especially for MHC-mismatched HSCT, the pace of the clinical introduction of novel therapeutics has been slow, likely due to the lack of a suitable translational model to rigorously test the immunologic and clinical impact of novel biologic therapies. Among the most promising of these therapies include those that

APA, Harvard, Vancouver, ISO, and other styles

49

Jhaveri, Amy, Esperanza B. Papadopoulos, Ann A. Jakubowski, et al. "Improved Survival in Patients with Refractory Cytopenias (Low Risk Myelodysplastic Syndrome - MDS) Treated with Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants (allo TCD-HSCTs),." Blood 118, no. 21 (2011): 3831. http://dx.doi.org/10.1182/blood.v118.21.3831.3831.

Full text

Abstract:

Abstract Abstract 3831 Background: Controversy exists regarding optimal treatment for pts with MDS with low blast percentages. Benefits of early transplant versus transplant-related morbidity and mortality have been debated. With increased time to transplant, MDS pts are more likely to undergo increased numbers of blood transfusions, experience more cytopenias, and are at risk of disease progression. Transplant offers a cure for MDS, and advances in supportive care during and after transplantation have afforded better outcomes and increased numbers of older pts to undergo transplant. Depletion

APA, Harvard, Vancouver, ISO, and other styles

50

Marton, Ashley, Jacob M. Pendergrast, Shaf Keshavjee, Lianne Singer, Janice Hawes, and Christine Cserti-Gazdewich. "Passenger Lymphocyte Syndrome Following Solid Organ Transplantation: Graft Source, Incidence, Specificity, Duration, and Severity Of Hemolysis." Blood 122, no. 21 (2013): 37. http://dx.doi.org/10.1182/blood.v122.21.37.37.

Full text

Abstract:

Abstract Background Passenger Lymphocyte Syndrome (PLS) is a rare complication of solid organ transplantation (SOT) and is marked by production of donor-derived antibodies towards host red blood cell (RBC) antigens. At Canada's largest SOT program, >400 transplants are conducted annually. The affiliated Transfusion Laboratory detects possible cases of PLS when previously seronegative hosts develop (delayed, non-transfusion-attributable) post-transplant antibodies (Ab) bearing unexpected, autoreactive (rather than alloreactive) RBC specificities. Donor attributability is established by disco

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!